Respective AUCs for losartan, its active metabolite and hydrochlorothiazide at these dosages in rats were approximately 35, 10 and 10 times greater than those achieved in humans with the administration of 100 mg of losartan in combination with 25 mg hydrochlorothiazide. A patient whose blood pressure is not adequately controlled with losartan 100 mg monotherapy (see above) may be switched to HYZAAR 100-12.5 once daily. Coadministration of losartan and cimetidine led to an increase of about 18% in AUC of losartan but did not affect the pharmacokinetics of its active metabolite. However, the LIFE study does not provide evidence that the benefits of COZAAR on reducing the risk of cardiovascular events in hypertensive patients with left ventricular hypertrophy apply to black patients. There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. The pharmacokinetics of losartan and its active metabolite are linear with oral losartan doses up to 200 mg and do not change over time. The mean age was 67 with 5704 (62%) age (>=)65. Patients were titrated at 2-week intervals if their SiDBP did not reach goal (<90 mmHg). Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Hypertensive Patients with Left Ventricular Hypertrophy HYZAAR is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. Adverse events were somewhat more frequent in the elderly compared to non-elderly patients and somewhat more frequent in Blacks compared to non-Blacks for both the losartan-hydrochlorothiazide and the control groups. In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of HYZAAR. However, the LIFE study provides no evidence that the benefits of losartan on reducing the risk of cardiovascular events in hypertensive patients with left ventricular hypertrophy apply to Black patients. Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy. The usual starting dose of losartan is 50 mg once daily, with 25 mg recommended for patients with intravascular volume depletion (e.g., patients treated with diuretics) (see WARNINGS, Hypotension -- Volume-Depleted Patients) and patients with a history of hepatic impairment (see WARNINGS, Impaired Hepatic Function). Merck also publishes unbiased health information as a not-for-profit service. Compared to normal subjects, the total plasma clearance of losartan in patients with hepatic insufficiency was about 50% lower, and the oral bioavailability was about 2 times higher. The HYZAAR 100-12.5 mg dosage tablet is not indicated for therapy in appropriate patients with severe hypertension. In long-term follow-up studies (without placebo control) the effect of losartan appeared to be maintained for up to a year. There was no difference in response for men and women or in patients over or under 65 years of age. The overall response to the combination was similar for Black and non-Black patients. Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin activity and consequent rise in angiotensin II plasma concentration in hypertensive patients. Giovanni, without stain or cunning, brightened his gaps in the generic hyzaar for sale hips or gradually incarnated. HYZAAR may be administered with other antihypertensive agents. Doses of 50, 100, and 150 mg once daily gave statistically significant systolic/diastolic mean decreases in blood pressure, compared to placebo in the range of 5.5-10.5/3.5-7.5 mmHg, with the 150 mg dose giving no greater effect than 50-100 mg. Twice-daily dosing at 50-100 mg/day gave consistently larger trough responses than once-daily dosing at the same total dose. Keep container tightly closed. Other antihypertensive drugs -- additive effect or potentiation.